Please see some useful resources below including the latest Open Orphan plc investor presentation, approved company descriptions, and images which can be used for editorial purposes as long as the connection to Open Orphan / hVIVO / Venn is clearly recognisable. Commercial use is prohibited.
|Open Orphan Investor Presentation||21.09.21||1.5 MB|
Images – hVIVO
|Cathal Friel – Executive Chairman Open Orphan plc||12.4 MB||JPG|
|Dr Andrew Catchpole – hVIVO Chief Scientist||6.6 MB||JPG|
|Adam French – hVIVO Director Laboratory Operations||9.8 MB||JPG|
|Danny Smith – Director of Volunteer Engagement & Retention||9.6 MB||JPG|
|FluCamp Nurse 1||16.7 MB||JPG|
|Nurse with sample||1.5 MB||JPG|
|hVIVO FluCamp 1||110kb||JPG|
|hVIVO FluCamp 2||288kb||JPG|
|hVIVO FluCamp 3||16.1 MB||JPG|
|FluCamp Volunteer 1||23.2 MB||JPG|
|Whitechapel Clinic screening room preview||20.1 MB||JPG|
|Whitechapel Clinic quarantine room 1||13.6 MB||JPG|
|Whitechapel Clinic quarantine room 2||13.1 MB||JPG|
|hVIVO Lab 1||20.9 MB||JPG|
|hVIVO Lab 2||9 MB||JPG|
|hVIVO Lab 3||18.7 MB||JPG|
|hVIVO Lab 4||17.2 MB||JPG|
|Open Orphan Logo||157KB||PNG|
|Venn Life Sciences Logo||126KB||JPG|
Open Orphan Description
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.
Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic, opened in February 2021, and its 24-bedroom QMB clinic which also has a highly specialised virology and immunology laboratory on-site. Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD. In addition, Open Orphan is also developing the world’s first COVID-19 human challenge study model as part of the Human Challenge Programme and has signed a reservation contract with the UK Government for the first three COVID-19 vaccine challenge studies.
Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company’s Disease in Motion® platform, this unique dataset includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma and biotech companies. Following COVID-19 there is now a renewed interest and investment in infectious diseases.
Open Orphan’s Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company’s Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial contracts.
For more information please visit our Company Overview page
|Click here to view our latest press releases.|